Trial · NCT02876835
Results by group236
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 236
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis) | Daprodustat | 10.86 | 95% Confidence Interval 9.80 to 12.02 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis) | Darbepoetin Alfa | 10.63 | 95% Confidence Interval 9.58 to 11.77 | Events per 100 person years | |
| Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52) | Daprodustat | 0.74 | Standard Error 0.019 | Grams per deciliter | |
| Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52) | Darbepoetin Alfa | 0.66 | Standard Error 0.019 | Grams per deciliter | |
| Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis) | Daprodustat | 10.86 | 95% Confidence Interval 9.80 to 12.02 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis) | Darbepoetin Alfa | 10.63 | 95% Confidence Interval 9.58 to 11.77 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period | Daprodustat | 12.34 | 95% Confidence Interval 11.19 to 13.57 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period | Darbepoetin Alfa | 11.77 | 95% Confidence Interval 10.65 to 12.98 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period | Daprodustat | 13.16 | 95% Confidence Interval 11.97 to 14.44 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period | Darbepoetin Alfa | 12.22 | 95% Confidence Interval 11.08 to 13.46 | Events per 100 person years | |
| Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period | Daprodustat | 17.55 | 95% Confidence Interval 15.74 to 19.51 | Events per 100 person years | |
| Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period | Darbepoetin Alfa | 17.76 | 95% Confidence Interval 15.97 to 19.70 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period | Daprodustat | 8.35 | 95% Confidence Interval 7.43 to 9.35 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period | Darbepoetin Alfa | 8.27 | 95% Confidence Interval 7.35 to 9.26 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period | Daprodustat | 3.02 | 95% Confidence Interval 2.48 to 3.65 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period | Darbepoetin Alfa | 2.55 | 95% Confidence Interval 2.06 to 3.13 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period | Daprodustat | 2.94 | 95% Confidence Interval 2.40 to 3.56 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period | Darbepoetin Alfa | 2.76 | 95% Confidence Interval 2.24 to 3.36 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period | Daprodustat | 1.26 | 95% Confidence Interval 0.92 to 1.69 | Events per 100 person years | |
| Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period | Darbepoetin Alfa | 0.95 | 95% Confidence Interval 0.66 to 1.33 | Events per 100 person years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02876835/results